Luke A. Masterson

1.8k total citations
30 papers, 856 citations indexed

About

Luke A. Masterson is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Luke A. Masterson has authored 30 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Organic Chemistry and 11 papers in Molecular Biology. Recurrent topics in Luke A. Masterson's work include Synthesis and pharmacology of benzodiazepine derivatives (15 papers), HER2/EGFR in Cancer Research (13 papers) and Cancer Treatment and Pharmacology (10 papers). Luke A. Masterson is often cited by papers focused on Synthesis and pharmacology of benzodiazepine derivatives (15 papers), HER2/EGFR in Cancer Research (13 papers) and Cancer Treatment and Pharmacology (10 papers). Luke A. Masterson collaborates with scholars based in United Kingdom, United States and Germany. Luke A. Masterson's co-authors include Philip W. Howard, John A. Hartley, Arnaud Tiberghien, David G. Williams, Lauren Adams, David E. Thurston, Simon Corbett, Neki V. Patel, Francesca Zammarchi and Nazzareno Dimasi and has published in prestigious journals such as Blood, Analytical Chemistry and Cancer Research.

In The Last Decade

Luke A. Masterson

30 papers receiving 804 citations

Peers

Luke A. Masterson
Arnaud Tiberghien United Kingdom
Jocelyn R. Setter United States
Barbara A. Leece United States
Kim K. Emmerton United States
Jonathan D. Bargh United Kingdom
Katharine C. Lai United States
Latha Sridharan United States
Arthur Kunz United States
Caroline Denevault‐Sabourin France
Maureen Dougher United States
Arnaud Tiberghien United Kingdom
Luke A. Masterson
Citations per year, relative to Luke A. Masterson Luke A. Masterson (= 1×) peers Arnaud Tiberghien

Countries citing papers authored by Luke A. Masterson

Since Specialization
Citations

This map shows the geographic impact of Luke A. Masterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke A. Masterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke A. Masterson more than expected).

Fields of papers citing papers by Luke A. Masterson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke A. Masterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke A. Masterson. The network helps show where Luke A. Masterson may publish in the future.

Co-authorship network of co-authors of Luke A. Masterson

This figure shows the co-authorship network connecting the top 25 collaborators of Luke A. Masterson. A scholar is included among the top collaborators of Luke A. Masterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke A. Masterson. Luke A. Masterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Yue, Jiaqi Yuan, Kathryn Ball, et al.. (2024). Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability In Vivo. Analytical Chemistry. 96(42). 16525–16533. 9 indexed citations
2.
Brown, Nicholas F., Elizabeth Murray, Philip W. Howard, et al.. (2024). Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer. Pancreatology. 24(3). 445–455. 5 indexed citations
3.
Gregson, Stephen J., Neki V. Patel, Balakumar Vijayakrishnan, et al.. (2022). Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer. Molecular Cancer Therapeutics. 21(9). 1439–1448. 4 indexed citations
4.
Moore, Kate M., Ami V. Desai, Beatriz de Luxán‐Delgado, et al.. (2020). Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Theranostics. 10(7). 2930–2942. 37 indexed citations
5.
Gregson, Stephen J., Allison Barrett, Neki V. Patel, et al.. (2019). Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers. European Journal of Medicinal Chemistry. 179. 591–607. 16 indexed citations
6.
7.
Kinneer, Krista, John Meekin, Arnaud Tiberghien, et al.. (2018). SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. Clinical Cancer Research. 24(24). 6570–6582. 58 indexed citations
8.
Kumar, Amit, Krista Kinneer, Luke A. Masterson, et al.. (2018). Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads. Bioorganic & Medicinal Chemistry Letters. 28(23-24). 3617–3621. 58 indexed citations
9.
Hartley, John A., Michael Flynn, John P. Bingham, et al.. (2018). Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Scientific Reports. 8(1). 10479–10479. 85 indexed citations
10.
Tyagi, Puneet, Sergei Pechenov, Jonathan Rios‐Doria, et al.. (2018). Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach. Journal of Pharmaceutical Sciences. 108(4). 1590–1597. 2 indexed citations
11.
Kumar, Amit, Krista Kinneer, Luke A. Masterson, et al.. (2018). Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs. Data in Brief. 21. 2208–2220. 3 indexed citations
12.
Gregson, Stephen J., Luke A. Masterson, BinQing Wei, et al.. (2017). Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers. Journal of Medicinal Chemistry. 60(23). 9490–9507. 27 indexed citations
13.
Flynn, Michael, Francesca Zammarchi, Peter Tyrer, et al.. (2016). ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics. 15(11). 2709–2721. 85 indexed citations
14.
Thompson, Pamela, Ian Hutchinson, Ryan Fleming, et al.. (2016). Straightforward Glycoengineering Approach to Site-Specific Antibody–Pyrrolobenzodiazepine Conjugates. ACS Medicinal Chemistry Letters. 7(11). 1005–1008. 28 indexed citations
15.
Hartley, John A., Marie Suggitt, Zhizhi Chen, et al.. (2010). SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity. Cancer Research. 70(17). 6849–6858. 43 indexed citations
16.
Howard, Philip W., Zhizhi Chen, Stephen J. Gregson, et al.. (2009). Synthesis of a novel C2/C2′-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. Bioorganic & Medicinal Chemistry Letters. 19(22). 6463–6466. 24 indexed citations
17.
Wells, Geoffrey, Philip W. Howard, Zara A. Sands, et al.. (2006). Design, Synthesis, and Biophysical and Biological Evaluation of a Series of Pyrrolobenzodiazepine−Poly(N-methylpyrrole) Conjugates. Journal of Medicinal Chemistry. 49(18). 5442–5461. 67 indexed citations
18.
Masterson, Luke A., Victoria J. Spanswick, John A. Hartley, et al.. (2005). Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy. Bioorganic & Medicinal Chemistry Letters. 16(2). 252–256. 19 indexed citations
19.
Masterson, Luke A., Stephen J. Croker, Terence C. Jenkins, Philip W. Howard, & David E. Thurston. (2004). Synthesis and biological evaluation of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) C8 cyclic amine conjugates. Bioorganic & Medicinal Chemistry Letters. 14(4). 901–904. 20 indexed citations
20.
Masterson, Luke A., et al.. (1996). Approaches to Short-Acting Neuromuscular Blocking Agents:  Nonsymmetrical Bis-tetrahydroisoquinolinium Mono- and Diesters. Journal of Medicinal Chemistry. 39(2). 556–561. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arnaud Tiberghien Breakdown of academic impact, for papers by Jocelyn R. Setter Breakdown of academic impact, for papers by Barbara A. Leece Breakdown of academic impact, for papers by Kim K. Emmerton Breakdown of academic impact, for papers by Jonathan D. Bargh Breakdown of academic impact, for papers by Katharine C. Lai Breakdown of academic impact, for papers by Latha Sridharan Breakdown of academic impact, for papers by Arthur Kunz Breakdown of academic impact, for papers by Caroline Denevault‐Sabourin Breakdown of academic impact, for papers by Maureen Dougher
Rankless by CCL
2026